Compile Data Set for Download or QSAR
Report error Found 328 Enz. Inhib. hit(s) with all data for entry = 10649
TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM455044(US10730874, Compound I-68 | US11352356, Compound I...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM455047(US10730874, Compound I-71 | US10730874, Compound I...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM455049(US10730874, Compound I-73 | US11352356, Compound I...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM557414(US11352356, Compound I-76)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
9/10/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM455051(US10730874, Compound I-75 | US11352356, Compound I...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM455054(US10730874, Compound I-78 | US11352356, Compound I...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM455056(US10730874, Compound I-80 | US11352356, Compound I...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM455057(US10730874, Compound I-81 | US11352356, Compound I...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM455028(US10730874, Compound I-52 | US11352356, Compound I...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM455027(US10730874, Compound I-51 | US11352356, Compound I...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM455033(US10730874, Compound I-57 | US11352356, Compound I...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM455036(US10730874, Compound I-60 | US11352356, Compound I...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM455035(US10730874, Compound I-59 | US11352356, Compound I...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM455042(US10730874, Compound I-66 | US11352356, Compound I...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM455041(US10730874, Compound I-65 | US11352356, Compound I...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM557438(US11352356, Compound I-100a)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM455075(US10730874, Compound I-99 | US11352356, Compound I...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM557440(US11352356, Compound I-100c)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM557290(US11352356, Compound I-100b)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM455080(US10730874, Compound I-102 | US11352356, Compound ...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM455079(US10730874, Compound I-101 | US11352356, Compound ...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM557444(US11352356, Compound I-104a)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM455081(US10730874, Compound I-103 | US11352356, Compound ...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM455084(US10730874, Compound I-105 | US11352356, Compound ...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM557445(US11352356, Compound I-104b)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM455086(US10730874, Compound I-107 | US11352356, Compound ...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM455085(US10730874, Compound I-106)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM455088(US10730874, Compound I-109 | US11352356, Compound ...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM455087(US10730874, Compound I-108 | US11352356, Compound ...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM455090(US10730874, Compound I-111 | US11352356, Compound ...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM455089(US10730874, Compound I-110 | US11352356, Compound ...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM455062(US10730874, Compound I-86)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM455061(US10730874, Compound I-85 | US11352356, Compound I...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM455063(US10730874, Compound I-87)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM454849(US10730874, Compound I-2 | US10730874, Compound I-...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM455068(US10730874, Compound I-92 | US11352356, Compound I...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM455069(US10730874, Compound I-93 | US11352356, Compound I...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM455074(US10730874, Compound I-98 | US11352356, Compound I...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM455073(US10730874, Compound I-97 | US11352356, Compound I...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM455108(US10730874, Compound I-129 | US11352356, Compound ...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM455107(US10730874, Compound I-128 | US11352356, Compound ...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM455110(US10730874, Compound I-131 | US11352356, Compound ...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM557468(US11352356, Compound I-133 | US11352356, Compound ...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM455111(US10730874, Compound I-132 | US11352356, Compound ...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM455114(US10730874, Compound I-135 | US11352356, Compound ...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM455113(US10730874, Compound I-134 | US11352356, Compound ...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM455116(US10730874, Compound I-137 | US11352356, Compound ...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM455115(US10730874, Compound I-136 | US11352356, Compound ...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM455118(US10730874, Compound I-139 | US11352356, Compound ...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM455117(US10730874, Compound I-138 | US11352356, Compound ...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
US Patent

Displayed 1 to 50 (of 328 total ) | Next | Last >>
Jump to: